文献速递骨软组织肉瘤与黑色素瘤

高危肺转移尤文肉瘤:大剂量化疗对比标准化疗联合全肺放疗的R2Pulm试验

High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.
PubMed 文献 · J Clin Oncol · 2019-09-25

R2Pulm试验纳入初诊仅肺/胸膜转移的尤文肉瘤患者,随机比较BuMel(白消安-美法仑大剂量化疗联合自体干细胞 rescue,不做全肺放疗)与标准化疗VAI联合全肺放疗。中位随访8.1年,两组无事件生存和总生存均无显著差异,BuMel组治疗相关死亡4例且严重急性毒性更多。结论认为对于肺/胸膜转移尤文肉瘤,BuMel相比常规VAI联合全肺放疗无明确获益。

要点

  • BuMel组4例治疗相关死亡,VAI+WLI组无治疗相关死亡,且BuMel组严重急性毒性显著更多。

核心结论

  • 对于仅肺或胸膜转移的尤文肉瘤患者,BuMel相比常规VAI联合全肺放疗在生存结局上无明确获益。

研究设计与样本

  • R2Pulm试验为随机对照III期试验,2000年至2015年纳入初诊仅肺/胸膜转移、年龄小于50岁的尤文肉瘤患者。
  • 543例潜在合格患者中287例随机分配至VAI+WLI组(n=143)或BuMel组(n=144),分析按意向治疗进行。
  • 随机前需接受轴向原发灶放疗的患者被排除,以避免放疗与白消安相互作用导致超额器官毒性。

主要发现

  • 中位随访8.1年,VAI+WLI组与BuMel组3年无事件生存率分别为50.6%与56.6%,8年分别为43.1%与52.9%。
  • BuMel组4例死于治疗相关毒性,VAI+WLI组无治疗相关死亡;BuMel组严重急性毒性显著更多。

关键数值与推荐

  • VAI+WLI组3年与8年无事件生存率分别为50.6%与43.1%,BuMel组分别为56.6%与52.9%。

临床怎么用

  • 对于仅肺/胸膜转移的尤文肉瘤,常规VAI联合全肺放疗仍是合理选择,BuMel不作明确优先推荐。
  • 选择BuMel需权衡其更高的严重急性毒性和治疗相关死亡风险。

局限性

  • 需轴向原发灶放疗的患者被排除随机,可能限制结果外推。
  • 原文未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy with WLI in Ewing sarcoma (ES) presenting with pulmonary and/or pleural metastases. METHODS: From 2000 to 2015, we enrolled patients younger than 50 years of age with newly diagnosed ES and with only pulmonary or pleural metastases. Patients received chemotherapy with six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel or seven courses of VAI and WLI (VAI plus WLI) by randomized assignment. The analysis was conducted as intention to treat. The estimates of the hazard ratio (HR), 95% CI, and P value were corrected for the three previous interim analyses by the inverse normal method. RESULTS: Of 543 potentially eligible patients, 287 were randomly assigned to VAI plus WLI (n = 143) or BuMel (n = 144). Selected patients requiring radiotherapy to an axial primary site were excluded from randomization to avoid excess organ toxicity from interaction between radiotherapy and busulfan. Median follow-up was 8.1 years. We did not observe any significant difference in survival outcomes between treatment groups. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for VAI plus WLI and BuMel patients, respectively, resulting in an HR of 0.79 (95% CI, 0.56 to 1.10; P = .16). For overall survival, the HR was 1.00 (95% CI, 0.70 to 1.44; P = .99). Four patients died as a result of BuMel-related toxicity, and none died after VAI plus WLI. Significantly more patients in the BuMel arm experienced severe acute toxicities than in the VAI plus WLI arm. CONCLUSION: In ES with pulmonary or pleural metastases, there is no clear benefit from BuMel compared with conventional VAI plus WLI.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Dirksen U, Brennan B, Le Deley MC, et al. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019. PMID: 31553693. doi:10.1200/JCO.19.00915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。